Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis

ग्रंथसूची विवरण
मुख्य लेखकों:	Sousos, N, Buck, G, Rodriguez-Meira, A, Norfo, R, Hamblin, A, Pezzella, F, Davies, J, Hublitz, P, Psaila, B, Mead, AJ
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	Wolters Kluwer Health 2020

समान संसाधन

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
द्वारा: Nikolaos Sousos, और अन्य
प्रकाशित: (2020-06-01)

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
प्रकाशित: (2021-05-01)

In utero origin of myelofibrosis presenting in adult monozygotic twins
द्वारा: Sousos, N, और अन्य
प्रकाशित: (2022)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
द्वारा: Claire Harrison
प्रकाशित: (2015-04-01)

Chronic Lymphocytic Leukemia and Myelofibrosis
द्वारा: Fares Darawshy, और अन्य
प्रकाशित: (2018-01-01)

Treatment and management of myelofibrosis in the era of JAK inhibitors
द्वारा: Keohane C, और अन्य
प्रकाशित: (2013-08-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
द्वारा: Andrew T. Kuykendall, और अन्य
प्रकाशित: (2021-08-01)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
द्वारा: Reilly, J, और अन्य
प्रकाशित: (2014)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
द्वारा: Keohane C, और अन्य
प्रकाशित: (2013-10-01)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
द्वारा: Reilly, J, और अन्य
प्रकाशित: (2014)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
द्वारा: Jui‐Che Chen, और अन्य
प्रकाशित: (2022-02-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
द्वारा: M. V. Barabanshchikova, और अन्य
प्रकाशित: (2016-03-01)

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis
द्वारा: Ristić Slobodan, और अन्य
प्रकाशित: (2015-01-01)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
द्वारा: Douglas Tremblay, और अन्य
प्रकाशित: (2023-06-01)

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
द्वारा: Louka, E, और अन्य
प्रकाशित: (2021)

Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets
द्वारा: Psaila, B, और अन्य
प्रकाशित: (2020)

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
द्वारा: Jay Y. Spiegel, और अन्य
प्रकाशित: (2017-09-01)

Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
द्वारा: Fuping Wang, और अन्य
प्रकाशित: (2024-12-01)

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
द्वारा: V. Pullarkat, और अन्य
प्रकाशित: (2022-06-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
द्वारा: Prithviraj Bose, और अन्य
प्रकाशित: (2020-08-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
द्वारा: Ayalew Tefferi, और अन्य
प्रकाशित: (2023-03-01)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
द्वारा: Marshall A. Lichtman
प्रकाशित: (2022-03-01)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
द्वारा: Naveen Pemmaraju, और अन्य
प्रकाशित: (2022-11-01)

Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing
द्वारा: Rodriguez-Meira, A, और अन्य
प्रकाशित: (2019)

Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis
द्वारा: Ke Chen, और अन्य
प्रकाशित: (2024-08-01)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
द्वारा: Derek W. Brown, और अन्य
प्रकाशित: (2022-09-01)

Acute massive myelofibrosis with acutelymphoblastic leukemia
द्वारा: Namık Özbek, और अन्य
प्रकाशित: (2009-12-01)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
द्वारा: Francesco Angotzi, और अन्य
प्रकाशित: (2022-02-01)

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis
द्वारा: Li, R, और अन्य
प्रकाशित: (2024)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
द्वारा: Psaila, B, और अन्य
प्रकाशित: (2017)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
द्वारा: Christopher Gerard Mullen, और अन्य
प्रकाशित: (2022-11-01)

Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
द्वारा: Ayesha Gul, और अन्य
प्रकाशित: (2022-06-01)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
द्वारा: Martina Barone, और अन्य
प्रकाशित: (2020-01-01)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
द्वारा: Marte Karen Brattås, और अन्य
प्रकाशित: (2018-11-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
द्वारा: O'Sullivan, JM, और अन्य
प्रकाशित: (2023)

CLINICAL AND PATHOMORPHOLOGICAL EXAMINATION OF MYELOFIBROSIS IN CHRONIC MYELOID LEUKEMIA
द्वारा: T. Yu. Dolgikh, और अन्य
प्रकाशित: (2016-02-01)

PATHOMORPHOLOGICAL ANALYSIS OF TREPANOBIOPTATES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA: ASSESSMENT OF THE PROGNOSTIC VALUE OF MYELOFIBROSIS WHEN COMPARED WITH CLINICAL DATA
द्वारा: T. Y. Dolgikh, और अन्य
प्रकाशित: (2019-02-01)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
द्वारा: Michael Gulrajani, और अन्य
प्रकाशित: (2023-08-01)

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
द्वारा: John O. Mascarenhas, और अन्य
प्रकाशित: (2017-02-01)

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
द्वारा: Chowdhury, O, और अन्य
प्रकाशित: (2020)